title: Systemic sclerosis disease modification clinical trials design: quo vadis?
authors.affiliation: Jefferson Institute of Molecular Medicine and Scleroderma Center, Thomas Jefferson University, Philadelphia, Pennsylvania 19107, USA.
authors.forename: Fabian A
authors.initials: FA
authors.lastname: Mendoza
authors.forename: Lynette L
authors.initials: LL
authors.lastname: Keyes-Elstein
authors.forename: Sergio A
authors.initials: SA
authors.lastname: Jimenez
mesh_terms: D018501:Antirheumatic Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D023381:Endpoint Determination; D006801:Humans; D016032:Randomized Controlled Trials as Topic; D015203:Reproducibility of Results; D012307:Risk Factors; D012595:Scleroderma, Systemic / Q000188:drug therapy*; D016896:Treatment Outcome; D028761:Withholding Treatment
chemical_list: D018501:Antirheumatic Agents